Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers.
Screening Period = up to 7 days All screening procedures must be executed within the shortest
possible time frame before the scheduled date for Visit 1 (drug administration). The
laboratory and instrumental examination data obtained within 14 days before the screening
will be recorded as the screening data.
The trial will include 110 volunteers that will be administered the study drug. Outpatient
observation will be done over the course of 4 visits: on day 10, 28, and 42 following drug
administration Along with that, the study will be continued in accordance with the Protocol,
accompanied by all the prescribed procedures and visits up to 180 days of observation.
Visit No. 0 (outpatient): screening Visit No. 1 (outpatient): vaccination Visits No. 2, 3, 4,
5, and 8: follow-up on days 10, 28, 42, 90, and180 after vaccination.
On days 120 and 150, visits 6 and 7 will be accomplished by telephone contact / telemedicine
conference or, if necessary, in the form of an in-person visit.
Any volunteer who received a dose of the study drug will be registered as a trial
participant, and his/her data will be used to help assess the drug's safety and tolerability.
Biological: Sputnik Light
solution for intramuscular injection Composition for 1 dose (0.5 ml)
Other Name: vector vaccine to help prevent the SARS-CoV-2-induced coronavirus infection
Inclusion Criteria:
1. Written informed consent given by the subject to participate in the trial;
2. Males and females aged 18 years old and older
3. Lack of COVID-2019 in medical history: negative IgM and IgG SARS CoV2 antibodies
enzyme-linked immunosorbent assay test result (no more than 14 days before being
included in the trial)
4. Negative COVID-2019 PCR test result during the screening visit
5. No contact with COVID-2019-infected persons within at least 14 days before being
included in the trial (according to what trial subjects state);
6. Negative HIV and hepatitis test results;
7. Consent to use effective contraception methods during the trial
8. Negative drugs or psychostimulants urine test during the screening visit;
9. Negative alcohol test during the screening visit;
10. Negative test for pregnancy (done for women with preserved reproductive potential)
11. No evident vaccine-induced reactions or complications after receiving immunobiological
products in the person's medical history;
12. No acute infectious and/or respiratory diseases within at least 14 days before being
included in the trial
Exclusion Criteria:
1. Any vaccination / immunization performed within 14 days prior to enrollment in the
study, or a planned vaccination within 14 days after being administered the study
drug;
2. Steroid therapy (except hormonal contraceptives or drugs used as hormone replacement
therapy for menopause) that has not been completed 30 days before enrollment;
3. Therapy with immunoglobulins or other blood products not completed 30 days before
enrollment in the trial
4. Immunosuppressor therapy that was completed within 3 months before being included in
the trial
5. A vaccination against COVID-2019 using any other drugs, including in the course of
other clinical studies
6. Female subjects during pregnancy or breastfeeding (for women with preserved
reproductive potential);
7. Acute coronary syndrome or stroke suffered less than one year before enrolling in the
trial
8. Tuberculosis, chronic systemic infections;
9. Complicated allergic history (severe life-threatening allergic reactions),
hypersensitivity or allergic reactions to the introduction of immunobiological drugs,
known allergic reactions to the components of the drug, exacerbation of allergic
diseases on the day of enrolling in the trial;
10. Neoplasms in a person's medical history (ICD codes C00-D09);
11. Donated blood or plasma (450+ ml) within 2 months before enrollment;
12. Splenectomy in the person's medical history;
13. Neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood
loss, severe anemia (hemoglobin <80 g/L), immunodeficiency in the medical history
within 6 months before the enrollment;
14. Active form of a disease caused by the human immunodeficiency virus, syphilis,
hepatitis B or C;
15. Anorexia, protein deficiency of any origin;
16. Large tattoos at the injection site (deltoid muscle area), which does not allow
assessing the localized response to administering the study drug/placebo
17. Alcohol or drug addiction in the person's medical history;
18. Registered with a psychiatrist
19. Participation in any other interventional clinical Trial within 90 days before the
start of this trial
20. Any other condition that the researching physician considers to be a hindrance to
completing the trial as per the protocol;
21. Research facility staff and other employees directly involved in the trial (research
team members) and their families.
22. Any related conditions that, in the opinion of the study physician, could serve as a
hindrance to participating in the trial.
ECO-Safety
Sankt Peterburg, Russian Federation